Publication Type:Journal Article
Source:Biomed Data J., Volume 1, Issue 2, p.07-09 (2015)
Keywords:cancer chemotherapy Prevention of chemoresistance HSP27 HSPB1 BVDU (RP101) pancreatic adenocarcinoma
A main obstacle in cancer chemotherapy is the rapid development of resistance by cancer cells. The heat shock protein HSP27 has been found as one of the key players driving resistance development. HSP27 is overexpressed in many kinds of cancer. It influences cellular processes like apoptosis, DNA repair, recombination, and metastasis. As a result, cancer cells evade apoptosis and develop resistance towards cytostatic drugs such as Gemcitabine (used as standard therapy in pancreatic cancer). To address this problem the HSP27-inhibitor BVDU ((E)-5-(2-Bromovinyl)-2′-deoxyuridine, RP101) was administered in combination with Gemcitabine to prevent resistance development. In the study design, the human pancreatic adenocarcinoma cell line Capan-2 was exposed to Gemcitabine alone and in combination with BVDU. Differential gene expression was displayed using DNA microarrays.This paper presents the resulting dataset, with pairwise comparison of control (untreated), Gemcitabine-, BVDU-, and Gemcitabine+BVDU - treated probes. The five spreadsheet files are openly accessible for validation, re-use and aggregation in future research.